• Explore /
  • Poster
  • / Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.

Abstract Poster

Authors

null

Eric Jonasch

The University of Texas MD Anderson Cancer Center, Houston, TX

Eric Jonasch , Giuseppe Procopio , Robert E. Hawkins , Angel Rodriguez Sanchez , Sergio Vazquez , Narayanan Srihari , Haralabos Kalofonos , Aristotelis Bamias , Petri Bono , Chaitali Babanrao Pisal , Yulia Hirschberg , Luca Dezzani , Qasim Iftikhar Ahmad , Manuela Schmidinger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01649778

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4561)

DOI

10.1200/JCO.2018.36.15_suppl.4561

Abstract #

4561

Poster Bd #

387

Abstract Disclosures

Similar Posters

First Author: Daniele Santini

First Author: Manuela Schmidinger

First Author: Thomas Hilser

First Author: Daniel M. Geynisman